바이러스 벡터 및 플라스미드 DNA 제조 시장 규모, 점유율 및 동향 분석 보고서 : 벡터 유형별, 워크플로우별, 용도별, 최종 용도별, 질병별, 지역별, 부문별 예측(2024-2030년)
Viral Vector And Plasmid DNA Manufacturing Market Size, Share & Trends Analysis Report By Vector Type (AAV, Lentivirus), By Workflow, By Application, By End-use, By Disease, By Region, And Segment Forecasts, 2024 - 2030
상품코드
:
1433658
리서치사
:
Grand View Research, Inc.
발행일
:
2024년 01월
페이지 정보
:
영문 120 Pages
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
바이러스 벡터 및 플라스미드 DNA 제조 시장의 성장과 동향:
Grand View Research, Inc.의 최신 보고서에 따르면, 세계 바이러스 벡터 및 플라스미드 DNA 제조 시장 규모는 2030년까지 195억 달러에 달할 것으로 예상되며, 2024년부터 2030년까지 CAGR 20.2 %로 성장할 것으로 예상됩니다.
유전자 치료용 플라스미드 DNA와 바이러스 벡터에 대한 수요가 증가함에 따라 업계 리더들은 플라스미드 DNA 제조를 촉진하는 새로운 기술을 발표하고 있습니다. 예를 들어, 2018년 4월 GE헬스케어 라이프사이언스는 바이러스 벡터를 기반으로 한 종양 바이러스, 세포 및 유전자 치료, 면역을 생산하기 위한 조립식 모듈형 바이오 공정 시설인 KUBio BSL 2를 발표했습니다.
세포 및 유전자 치료 연구 분야에 대한 투자가 증가함에 따라 시장에서는 바이러스 벡터에 대한 전례 없는 수요가 발생하고 있습니다. 이에 따라 다양한 기관들이 이러한 벡터의 제조 공정 개발을 가속화하기 위해 자금을 지원하고 있습니다. 예를 들어, 2019년 9월 Next Generation Manufacturing Canada는 iVexSol Canada가 이끄는 컨소시엄에 189만 달러를 지원했습니다. 이 자금은 렌치 바이러스 벡터의 고급 제조 공정 개발을 위해 제공되었습니다. 2iVexSol Canada는 벡터 제조 회사로 여러 회사와 협력하여 고급 LVV 제조 플랫폼을 개발하고 있습니다.
또한 Thermo Fisher Scientific, QIAGEN NV, Agilent Technology, Takara Bio, Oxford Biomedica 등 이 시장에서 활동하는 주요 기업들은 새로운 유전자 도입 플랫폼 개발에 주력하고 있습니다. 이들 기업은 증가하는 시장 수요에 대응하기 위해 생물학적 유전자 도입 시스템의 생산 규모를 확대하기 위해 막대한 투자를 하고 있습니다. 예를 들어, 타카라 바이오는 2020년 5월 시가현에 유전자 및 세포 치료 처리 II 센터(CGCPII) 건설을 완료했습니다. 이 센터는 회사의 GMP 바이러스 벡터 생산 시설에 추가되는 것입니다. 마찬가지로 Thermo Fisher Scientific은 2020년 5월에 1억 8,000만 달러를 투자하여 바이러스 벡터 생산 능력을 두 배로 확대했습니다. 이러한 이니셔티브의 증가는 예측 기간 동안 시장 성장을 촉진할 것으로 예상됩니다.
또한, 바이러스 벡터의 대량 생산은 업스트림 공정과 다운스트림 공정에서 어려움에 직면해 있습니다. 업스트림 공정에서 바이러스 벡터 생산에 사용되는 방법은 제조업체에게 큰 장애물 중 하나입니다. 접착 세포 배양을 대규모로 재현하는 것은 해결해야 할 중요한 문제입니다. 따라서 연구자들은 대형 바이오리액터를 사용하여 이러한 세포를 배양하기 위해 노력하고 있습니다. 또한, 다운스트림 공정에서 이러한 벡터의 순도를 더 잘 이해해야 합니다.
바이러스 벡터 및 플라스미드 DNA 제조 시장 보고서 하이라이트:
- 벡터 유형별로는 아데노부수체 바이러스(AAV) 부문이 높은 수요로 인해 2023년 20.0%의 매출 점유율로 시장을 주도했으며, 임상시험에서의 활용이 확대되고 있습니다.
- 워크플로우를 기준으로 볼 때, 다운스트림 처리 기술의 발전과 일회용 시스템 채택으로 인해 2023년 다운스트림 처리 분야가 워크플로우 분야에서 가장 큰 매출 점유율을 차지하며 시장을 주도했습니다.
- 용도별로는 백신 치료 분야가 2023년 가장 큰 매출 점유율로 시장을 장악했으며, 세포 치료는 예측 기간 동안 가장 빠른 CAGR로 성장할 것으로 예상됩니다.
- 최종 용도별로는 연구 기관 부문이 2023년 가장 큰 매출 점유율로 시장을 장악했습니다. 반면, 제약 및 바이오 제약 회사는 예측 기간 동안 가장 빠른 CAGR로 성장할 것으로 예상됩니다.
- 질환별로는 암 분야가 2023년 가장 큰 매출 점유율로 시장을 장악하고 예측 기간 동안 가장 빠른 CAGR로 성장할 것으로 예상됩니다.
- 북미 지역은 암과 감염성 질환에 대한 높은 부담, 높은 구매력 평가, 양질의 의료서비스에 대한 정부 지원, 상환 가능 등의 요인으로 인해 시장을 독점하고 있습니다.
목차
제1장 조사 방법과 범위
제2장 주요 요약
제3장 바이러스 벡터 및 플라스미드 DNA 제조 시장 변수, 동향 및 범위
- 시장 계통 전망
- 시장 역학
- 시장 성장 촉진요인 분석
- 시장 성장 억제요인 분석
- 바이러스 벡터 및 플라스미드 DNA 제조 시장 분석 툴
- 업계 분석 - Porter's Five Forces 분석
- PESTEL 분석
- COVID-19의 영향 분석
제4장 바이러스 벡터 및 플라스미드 DNA 제조 시장 : 벡터 유형 추정·동향 분석
- 벡터 유형별 세계의 바이러스 벡터 및 플라스미드 DNA 제조 시장 전망
- 아데노연관바이러스(AAV)
- 렌티바이러스
- 아데노바이러스
- 레트로바이러스
- 플라스미드
- 기타
제5장 바이러스 벡터 및 플라스미드 DNA 제조 시장 : 워크플로우 추정·동향 분석
- 워크플로우별 세계의 바이러스 벡터 및 플라스미드 DNA 제조 시장 전망
- 업스트림 처리
- 다운스트림 처리
제6장 바이러스 벡터 및 플라스미드 DNA 제조 시장 : 용도 추정·동향 분석
- 용도별 세계의 바이러스 벡터 및 플라스미드 DNA 제조 시장 전망
- 유전자 치료
- 세포 치료
- 백신
- 연구 용도
제7장 바이러스 벡터 및 플라스미드 DNA 제조 시장 : 최종 용도 추정·동향 분석
- 최종 용도별 세계의 바이러스 벡터 및 플라스미드 DNA 제조 시장 전망
- 제약 기업·바이오의약품 기업
- 연구기관
제8장 바이러스 벡터 및 플라스미드 DNA 제조 시장 : 질환 추정·동향 분석
- 질환별 세계의 바이러스 벡터 및 플라스미드 DNA 제조 시장 전망
- 암
- 유전성 질환
- 감염증
- 기타
제9장 바이러스 벡터 및 플라스미드 DNA 제조 시장 : 지역 추정·동향 분석
- 지역 시장 점유율 분석, 2023년 및 2030년
- 북미
- 유럽
- 영국
- 독일
- 프랑스
- 이탈리아
- 스페인
- 노르웨이
- 스웨덴
- 덴마크
- 아시아태평양
- 라틴아메리카
- 중동 및 아프리카
- 남아프리카공화국
- 사우디아라비아
- 아랍에미리트
- 쿠웨이트
제10장 경쟁 상황
- 기업 분류
- 전략 매핑
- 기업의 시장 포지션 분석, 2023년
- 기업 개요·리스트
- Merck KGaA
- Lonza
- FUJIFILM Diosynth Biotechnologies
- Thermo Fisher Scientific
- Cobra Biologics
- Catalent Inc.
- Wuxi Biologics
- Takara Bio Inc.
- Waisman Biomanufacturing
- Genezen laboratories
- Batavia Biosciences
- Miltenyi Biotec GmbH
- SIRION Biotech GmbH
- Virovek Incorporation
- BioNTech IMFS GmbH
- Audentes Therapeutics
- BioMarin Pharmaceutical
- RegenxBio, Inc.
ksm
영문 목차
Viral Vector And Plasmid DNA Manufacturing Market Growth & Trends:
The global viral vector and plasmid DNA manufacturing market size is anticipated to reach USD 19.5 billion by 2030 and it is projected to grow at a CAGR of 20.2% from 2024 - 2030, according to a new report by Grand View Research, Inc. With the increasing demand for plasmid DNA and viral vectors for gene therapy, industry leaders have launched new technologies to boost plasmid DNA manufacturing. For instance, in April 2018, GE Healthcare Life Sciences introduced KUBio BSL 2, a prefabricated, modular bioprocessing facility for the production of oncolytic viruses, cell and gene treatments, and immunizations based on viral vectors.
With the increase in investments in cell and gene therapy research space, there is unprecedented demand for viral vectors in the market. Owing to this, various organizations are providing funds to accelerate developments in the manufacturing processes for these vectors. For instance, in September 2019, Next Generation Manufacturing Canada provided USD 1.89 million to a consortium led by iVexSol Canada. This fund was provided for the development of an advanced manufacturing process for lentiviral vectors. 2iVexSol Canada is a vector manufacturing company that has collaborated with several companies to develop an advanced LVV manufacturing platform.
Moreover, the major companies operating in this market, such as Thermo Fisher Scientific, QIAGEN NV, Agilent Technologies, Takara Bio, Inc., and Oxford Biomedica, are focusing on developing new gene delivery platforms. These companies are making huge investments to scale up the production of biological gene delivery systems to meet the increasing market demand. For instance, in May 2020, Takara Bio, Inc. completed the Center for Gene and Cell Therapy Processing II (CGCPII) construction in Shiga, Japan. This center is an addition to its GMP viral vector production facility. Similarly, in May 2020, Thermo Fisher Scientific also invested USD 180 million to scale up its viral vector manufacturing capacity twofold. Such increasing initiatives are anticipated to propel market growth in the forecast period.
Furthermore, large-scale production of viral vectors is facing challenges in upstream and downstream processing. In upstream processes, the method used for viral vector production is one of the major hurdles for manufacturers. Reproduction of adherent cell cultures at a large scale is a key concern that needs to be addressed. Thus, researchers are trying to grow these cells using large bioreactors. In addition, there is a need for a better understanding of the purity of these vectors in downstream processing.
Viral Vector And Plasmid DNA Manufacturing Market Report Highlights:
- Based on the vector type, the adeno-associated virus (AAV) segment dominated the market with a 20.0% revenue share in 2023 due to high demand, and their usage in clinical trials is growing
- Based on the workflow, the downstream processing segment led the market in 2023 with the largest revenue share in workflow segment due to advancements in downstream processing technologies and the adoption of single-use systems
- Based on the application, the vaccinology segment dominated the application segment in 2023 with the largest revenue share, and cell therapy is expected to grow at fastest CAGR during the forecast period
- Based on the end-use, the research institutes segment dominated the market with the largest revenue share in 2023. On the other hand, the pharmaceutical and biopharmaceutical companies are expected to grow at a fastest CAGR over the forecast period
- In terms of disease, the cancer segment dominated the market with the largest revenue share in 2023 and it is anticipated to grow at fastest CAGR during the forecast period
- North America dominated the market owing to factors such as the significant burden of cancer, and infectious diseases, high purchasing power parity, government support for quality healthcare, and availability of reimbursement
Table of Contents
Chapter 1. Methodology and Scope
- 1.1. Market Segmentation & Scope
- 1.2. Segment Definitions
- 1.2.1. Vector type
- 1.2.2. Workflow
- 1.2.3. Application
- 1.2.4. End-use
- 1.2.5. Disease
- 1.2.6. Estimates and forecasts timeline
- 1.3. Research Methodology
- 1.4. Information Procurement
- 1.4.1. Purchased database
- 1.4.2. GVR's internal database
- 1.4.3. Secondary sources
- 1.4.4. Primary research
- 1.4.5. Details of primary research
- 1.5. Information or Data Analysis
- 1.5.1. Data analysis models
- 1.6. Market Formulation & Validation
- 1.7. Model Details
- 1.7.1. Commodity flow analysis (Model 1)
- 1.7.2. Approach 1: Commodity flow approach
- 1.7.3. Volume price analysis (Model 2)
- 1.7.4. Approach 2: Volume price analysis
- 1.8. List of Secondary Sources
- 1.9. List of Primary Sources
- 1.10. Objectives
Chapter 2. Executive Summary
- 2.1. Market Outlook
- 2.2. Segment Outlook
- 2.3. Competitive Insights
Chapter 3. Viral Vectors And Plasmid DNA Manufacturing Market Variables, Trends & Scope
- 3.1. Market Lineage Outlook
- 3.1.1. Parent market outlook
- 3.1.2. Related/ancillary market outlook
- 3.2. Market Dynamics
- 3.2.1. Market driver analysis
- 3.2.1.1. Robust Pipeline for Gene Therapies and Viral Vector Vaccines
- 3.2.1.2. Technological Advancements in Manufacturing Vectors
- 3.2.1.3. Highly Competitive Market and Various Strategies Undertaken by Market Entities
- 3.2.2. Market restraint analysis
- 3.2.2.1. Regulatory, Scientific, And Ethical Challenges Associated With Gene Therapy And Viral Vectors
- 3.3. Viral Vectors And Plasmid DNA Manufacturing Market Analysis Tools
- 3.3.1. Industry Analysis - Porter's
- 3.3.2. PESTEL Analysis
- 3.3.3. COVID-19 Impact Analysis
Chapter 4. Viral Vectors And Plasmid DNA Manufacturing Market: Vector Type Estimates & Trend Analysis
- 4.1. Global Viral Vectors And Plasmid DNA Manufacturing Market by Vector Type Outlook
- 4.2. Adeno-associated virus (AAV)
- 4.2.1. Market estimates and forecasts 2018 to 2030, (USD Million)
- 4.3. Lentivirus
- 4.3.1. Market estimates and forecasts 2018 to 2030, (USD Million)
- 4.4. Adenovirus
- 4.4.1. Market estimates and forecasts 2018 to 2030, (USD Million)
- 4.5. Retrovirus
- 4.5.1. Market estimates and forecasts 2018 to 2030, (USD Million)
- 4.6. Plasmids
- 4.6.1. Market estimates and forecasts 2018 to 2030, (USD Million)
- 4.7. Others
- 4.7.1. Market estimates and forecasts 2018 to 2030, (USD Million)
Chapter 5. Viral Vectors And Plasmid DNA Manufacturing Market: Workflow Estimates & Trend Analysis
- 5.1. Global Viral Vectors And Plasmid DNA Manufacturing Market by Workflow Outlook
- 5.2. Upstream Manufacturing
- 5.2.1. Market estimates and forecasts 2018 to 2030, (USD Million)
- 5.2.2. Vector Amplification & Expansion
- 5.2.2.1. Market estimates and forecasts 2018 to 2030, (USD Million)
- 5.2.3. Vector Recovery/Harvesting
- 5.2.3.1. Market estimates and forecasts 2018 to 2030, (USD Million)
- 5.3. Downstream Manufacturing
- 5.3.1. Market estimates and forecasts 2018 to 2030, (USD Million)
- 5.3.2. Purification
- 5.3.2.1. Market estimates and forecasts 2018 to 2030, (USD Million)
- 5.3.3. Fill Finish diagnostic instruments
- 5.3.3.1. Market estimates and forecasts 2018 to 2030, (USD Million)
Chapter 6. Viral Vectors And Plasmid DNA Manufacturing Market: Application Estimates & Trend Analysis
- 6.1. Global Viral Vectors And Plasmid DNA Manufacturing Market by Application Outlook
- 6.2. Gene Therapy
- 6.2.1. Market estimates and forecasts 2018 to 2030, (USD Million)
- 6.3. Cell Therapy
- 6.3.1. Market estimates and forecasts 2018 to 2030, (USD Million)
- 6.4. Vaccinology
- 6.4.1. Market estimates and forecasts 2018 to 2030, (USD Million)
- 6.5. Research Applications
- 6.5.1. Market estimates and forecasts 2018 to 2030, (USD Million)
Chapter 7. Viral Vectors And Plasmid DNA Manufacturing Market: End-use Estimates & Trend Analysis
- 7.1. Global Viral Vectors And Plasmid DNA Manufacturing Market by End-use Outlook
- 7.2. Pharmaceutical and Biopharmaceutical Companies
- 7.2.1. Market estimates and forecasts 2018 to 2030, (USD Million)
- 7.3. Research Institutes
- 7.3.1. Market estimates and forecasts 2018 to 2030, (USD Million)
Chapter 8. Viral Vectors And Plasmid DNA Manufacturing Market: Disease Estimates & Trend Analysis
- 8.1. Global Viral Vectors And Plasmid DNA Manufacturing Market by Disease Outlook
- 8.2. Cancer
- 8.2.1. Market estimates and forecasts 2018 to 2030, (USD Million)
- 8.3. Genetic Disorders
- 8.3.1. Market estimates and forecasts 2018 to 2030, (USD Million)
- 8.4. Infectious Diseases
- 8.4.1. Market estimates and forecasts 2018 to 2030, (USD Million)
- 8.5. Other
- 8.5.1. Market estimates and forecasts 2018 to 2030, (USD Million)
Chapter 9. Viral Vectors And Plasmid DNA Manufacturing Market: Regional Estimates & Trend Analysis
- 9.1. Regional Market Share Analysis, 2023 & 2030
- 9.2. North America
- 9.2.1. North America market estimates and forecasts 2018 to 2030, (USD Million)
- 9.2.2. U.S.
- 9.2.2.1. Key country dynamics
- 9.2.2.2. Regulatory framework
- 9.2.2.3. Competitive scenario
- 9.2.2.4. U.S. market estimates and forecasts 2018 to 2030, (USD Million)
- 9.2.2.5. Target disease prevalence
- 9.2.3. Canada
- 9.2.3.1. Key country dynamics
- 9.2.3.2. Regulatory framework
- 9.2.3.3. Competitive scenario
- 9.2.3.4. Canada market estimates and forecasts 2018 to 2030, (USD Million)
- 9.2.3.5. Target disease prevalence
- 9.3. Europe
- 9.3.1. Europe market estimates and forecasts 2018 to 2030, (USD Million)
- 9.3.2. UK
- 9.3.2.1. Key country dynamics
- 9.3.2.2. Regulatory framework
- 9.3.2.3. Competitive scenario
- 9.3.2.4. UK market estimates and forecasts 2018 to 2030, (USD Million)
- 9.3.2.5. Target disease prevalence
- 9.3.3. Germany
- 9.3.3.1. Key country dynamics
- 9.3.3.2. Regulatory framework
- 9.3.3.3. Competitive scenario
- 9.3.3.4. Germany market estimates and forecasts 2018 to 2030, (USD Million)
- 9.3.3.5. Target disease prevalence
- 9.3.4. France
- 9.3.4.1. Key country dynamics
- 9.3.4.2. Regulatory framework
- 9.3.4.3. Competitive scenario
- 9.3.4.4. France market estimates and forecasts 2018 to 2030, (USD Million)
- 9.3.4.5. Target disease prevalence
- 9.3.5. Italy
- 9.3.5.1. Key country dynamics
- 9.3.5.2. Regulatory framework
- 9.3.5.3. Competitive scenario
- 9.3.5.4. Italy market estimates and forecasts 2018 to 2030, (USD Million)
- 9.3.5.5. Target disease prevalence
- 9.3.6. Spain
- 9.3.6.1. Key country dynamics
- 9.3.6.2. Regulatory framework
- 9.3.6.3. Competitive scenario
- 9.3.6.4. Spain market estimates and forecasts 2018 to 2030, (USD Million)
- 9.3.6.5. Target disease prevalence
- 9.3.7. Norway
- 9.3.7.1. Key country dynamics
- 9.3.7.2. Regulatory framework
- 9.3.7.3. Competitive scenario
- 9.3.7.4. Norway market estimates and forecasts 2018 to 2030, (USD Million)
- 9.3.7.5. Target disease prevalence
- 9.3.8. Sweden
- 9.3.8.1. Key country dynamics
- 9.3.8.2. Regulatory framework
- 9.3.8.3. Competitive scenario
- 9.3.8.4. Sweden market estimates and forecasts 2018 to 2030, (USD Million)
- 9.3.8.5. Target disease prevalence
- 9.3.9. Denmark
- 9.3.9.1. Key country dynamics
- 9.3.9.2. Regulatory framework
- 9.3.9.3. Competitive scenario
- 9.3.9.4. Denmark market estimates and forecasts 2018 to 2030, (USD Million)
- 9.3.9.5. Target disease prevalence
- 9.4. Asia Pacific
- 9.4.1. Asia Pacific market estimates and forecasts 2018 to 2030, (USD Million)
- 9.4.2. Japan
- 9.4.2.1. Key country dynamics
- 9.4.2.2. Regulatory framework
- 9.4.2.3. Competitive scenario
- 9.4.2.4. Japan market estimates and forecasts 2018 to 2030, (USD Million)
- 9.4.2.5. Target disease prevalence
- 9.4.3. China
- 9.4.3.1. Key country dynamics
- 9.4.3.2. Regulatory framework
- 9.4.3.3. Competitive scenario
- 9.4.3.4. China market estimates and forecasts 2018 to 2030, (USD Million)
- 9.4.3.5. Target disease prevalence
- 9.4.4. India
- 9.4.4.1. Key country dynamics
- 9.4.4.2. Regulatory framework
- 9.4.4.3. Competitive scenario
- 9.4.4.4. India market estimates and forecasts 2018 to 2030, (USD Million)
- 9.4.4.5. Target disease prevalence
- 9.4.5. Australia
- 9.4.5.1. Key country dynamics
- 9.4.5.2. Regulatory framework
- 9.4.5.3. Competitive scenario
- 9.4.5.4. Australia market estimates and forecasts 2018 to 2030, (USD Million)
- 9.4.5.5. Target disease prevalence
- 9.4.6. South Korea
- 9.4.6.1. Key country dynamics
- 9.4.6.2. Regulatory framework
- 9.4.6.3. Competitive scenario
- 9.4.6.4. South Korea market estimates and forecasts 2018 to 2030, (USD Million)
- 9.4.6.5. Target disease prevalence
- 9.4.7. Thailand
- 9.4.7.1. Key country dynamics
- 9.4.7.2. Regulatory framework
- 9.4.7.3. Competitive scenario
- 9.4.7.4. Thailand market estimates and forecasts 2018 to 2030, (USD Million)
- 9.4.7.5. Target disease prevalence
- 9.5. Latin America
- 9.5.1. Latin America market estimates and forecasts 2018 to 2030, (USD Million)
- 9.5.2. Brazil
- 9.5.2.1. Key country dynamics
- 9.5.2.2. Regulatory framework
- 9.5.2.3. Competitive scenario
- 9.5.2.4. Brazil market estimates and forecasts 2018 to 2030, (USD Million)
- 9.5.2.5. Target disease prevalence
- 9.5.3. Mexico
- 9.5.3.1. Key country dynamics
- 9.5.3.2. Regulatory framework
- 9.5.3.3. Competitive scenario
- 9.5.3.4. Mexico market estimates and forecasts 2018 to 2030, (USD Million)
- 9.5.3.5. Target disease prevalence
- 9.5.4. Argentina
- 9.5.4.1. Key country dynamics
- 9.5.4.2. Regulatory framework
- 9.5.4.3. Competitive scenario
- 9.5.4.4. Argentina market estimates and forecasts 2018 to 2030, (USD Million)
- 9.5.4.5. Target disease prevalence
- 9.6. MEA
- 9.6.1. MEA market estimates and forecasts 2018 to 2030, (USD Million)
- 9.6.2. South Africa
- 9.6.2.1. Key country dynamics
- 9.6.2.2. Regulatory framework
- 9.6.2.3. Competitive scenario
- 9.6.2.4. South Africa market estimates and forecasts 2018 to 2030, (USD Million)
- 9.6.2.5. Target disease prevalence
- 9.6.3. Saudi Arabia
- 9.6.3.1. Key country dynamics
- 9.6.3.2. Regulatory framework
- 9.6.3.3. Competitive scenario
- 9.6.3.4. Saudi Arabia market estimates and forecasts 2018 to 2030, (USD Million)
- 9.6.3.5. Target disease prevalence
- 9.6.4. UAE
- 9.6.4.1. Key country dynamics
- 9.6.4.2. Regulatory framework
- 9.6.4.3. Competitive scenario
- 9.6.4.4. UAE market estimates and forecasts 2018 to 2030, (USD Million)
- 9.6.4.5. Target disease prevalence
- 9.6.5. Kuwait
- 9.6.5.1. Key country dynamics
- 9.6.5.2. Regulatory framework
- 9.6.5.3. Competitive scenario
- 9.6.5.4. Kuwait market estimates and forecasts 2018 to 2030, (USD Million)
- 9.6.5.5. Target disease prevalence
Chapter 10. Competitive Landscape
- 10.1. Company Categorization
- 10.2. Strategy Mapping
- 10.3. Company Market Position Analysis, 2023
- 10.4. Company Profiles/Listing
- 10.4.1. Merck KGaA
- 10.4.1.1. Company overview
- 10.4.1.2. Financial performance
- 10.4.1.3. Product benchmarking
- 10.4.1.4. Strategic initiatives
- 10.4.2. Lonza
- 10.4.2.1. Company overview
- 10.4.2.2. Financial performance
- 10.4.2.3. Product benchmarking
- 10.4.2.4. Strategic initiatives
- 10.4.3. FUJIFILM Diosynth Biotechnologies
- 10.4.3.1. Company overview
- 10.4.3.2. Financial performance
- 10.4.3.3. Product benchmarking
- 10.4.3.4. Strategic initiatives
- 10.4.4. Thermo Fisher Scientific
- 10.4.4.1. Company overview
- 10.4.4.2. Financial performance
- 10.4.4.3. Product benchmarking
- 10.4.4.4. Strategic initiatives
- 10.4.5. Cobra Biologics
- 10.4.5.1. Company overview
- 10.4.5.2. Financial performance
- 10.4.5.3. Product benchmarking
- 10.4.5.4. Strategic initiatives
- 10.4.6. Catalent Inc.
- 10.4.6.1. Company overview
- 10.4.6.2. Financial performance
- 10.4.6.3. Product benchmarking
- 10.4.6.4. Strategic initiatives
- 10.4.7. Wuxi Biologics
- 10.4.7.1. Company overview
- 10.4.7.2. Financial performance
- 10.4.7.3. Product benchmarking
- 10.4.7.4. Strategic initiatives
- 10.4.8. Takara Bio Inc.
- 10.4.8.1. Company overview
- 10.4.8.2. Financial performance
- 10.4.8.3. Product benchmarking
- 10.4.8.4. Strategic initiatives
- 10.4.9. Waisman Biomanufacturing
- 10.4.9.1. Company overview
- 10.4.9.2. Financial performance
- 10.4.9.3. Product benchmarking
- 10.4.9.4. Strategic initiatives
- 10.4.10. Genezen laboratories
- 10.4.10.1. Company overview
- 10.4.10.2. Financial performance
- 10.4.10.3. Product benchmarking
- 10.4.10.4. Strategic initiatives
- 10.4.11. Batavia Biosciences
- 10.4.11.1. Company overview
- 10.4.11.2. Financial performance
- 10.4.11.3. Product benchmarking
- 10.4.11.4. Strategic initiatives
- 10.4.12. Miltenyi Biotec GmbH
- 10.4.12.1. Company overview
- 10.4.12.2. Financial performance
- 10.4.12.3. Product benchmarking
- 10.4.12.4. Strategic initiatives
- 10.4.13. SIRION Biotech GmbH
- 10.4.13.1. Company overview
- 10.4.13.2. Financial performance
- 10.4.13.3. Product benchmarking
- 10.4.13.4. Strategic initiatives
- 10.4.14. Virovek Incorporation
- 10.4.14.1. Company overview
- 10.4.14.2. Financial performance
- 10.4.14.3. Product benchmarking
- 10.4.14.4. Strategic initiatives
- 10.4.15. BioNTech IMFS GmbH
- 10.4.15.1. Company overview
- 10.4.15.2. Financial performance
- 10.4.15.3. Product benchmarking
- 10.4.15.4. Strategic initiatives
- 10.4.16. Audentes Therapeutics
- 10.4.16.1. Company overview
- 10.4.16.2. Financial performance
- 10.4.16.3. Product benchmarking
- 10.4.16.4. Strategic initiatives
- 10.4.17. BioMarin Pharmaceutical
- 10.4.17.1. Company overview
- 10.4.17.2. Financial performance
- 10.4.17.3. Product benchmarking
- 10.4.17.4. Strategic initiatives
- 10.4.18. RegenxBio, Inc.
- 10.4.18.1. Company overview
- 10.4.18.2. Financial performance
- 10.4.18.3. Product benchmarking
- 10.4.18.4. Strategic initiatives
관련자료
